Date:5/21/2012

strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.Retail Investor and Media Contact:Institutional Investor Contact:GenVec, Inc. 

S.A. Noonan CommunicationsDouglas J. Swirsky 

Susan A. Noonan(240) 632-55(212) 966-3650dswirsky@genvec.com 

susa
'/>"/>

SOURCE GenVec, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
2. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
4. GenVec Reports Third Quarter 2010 Financial Results
5. GenVec Forms Collaboration With World-Leading Animal Health Company
6. GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
7. GenVec to Host First Quarter 2011 Earnings Call and Webcast
8. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
9. GenVec Reports Second Quarter 2011 Financial Results
10. GenVec to Present at Stifel Nicolaus 2011 Healthcare Conference
11. GenVec to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 9, 2011